8-K: HilleVax to be Acquired by XOMA Royalty for Cash & CVR

HilleVax, a clinical-stage biopharmaceutical company, has entered into a definitive merger agreement to be acquired by XOMA Royalty Corporation for $1.95 per share in cash plus a contingent value right.

Summary

• HilleVax, Inc. (HLVX) will be acquired by XOMA Royalty Corporation (XOMA) and its wholly-owned subsidiary, XRA 4 Corp., through a cash tender offer and subsequent merger.
• HilleVax stockholders will receive $1.95 in cash per share of common stock, plus one non-transferable Contingent Value Right (CVR).
• The CVR provides potential future cash payments based on: (i) HilleVax's net cash exceeding $102.95 million at closing; (ii) 90% to 100% of savings from HilleVax's Boston office lease obligations, including sublease proceeds; and (iii) 90% of net proceeds from any sale, transfer, license, or disposition of HilleVax's norovirus vaccine programs (HIL-216) within five years post-regulatory approval, if the disposition or financing occurs within two years post-closing.
• HilleVax's Board of Directors unanimously approved the merger, deeming it fair and in the best interests of stockholders, and recommended stockholders accept the offer.
• Officers, directors, and certain stockholders, collectively holding approximately 22.9% of HilleVax common stock, have signed support agreements to tender their shares.
• The tender offer is expected to commence by August 18, 2025, with the acquisition anticipated to close in September 2025.
• The merger will be effected under Section 251(h) of the Delaware General Corporation Law (DGCL), eliminating the need for additional HilleVax stockholder approvals.
• The License Agreement with Takeda Vaccines, Inc. for HIL-214 (formerly TAK-214) was terminated on August 1, 2025, effective six months after notice, with no material early termination penalties.
• HilleVax entered into a Sublease Agreement with Stellaromics, Inc. on July 31, 2025, for approximately 19,534 rentable square feet of its Boston office, with a term expected to extend for three years and two months following commencement (anticipated November 1, 2025).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is being acquired and winding down its primary development, the deal provides immediate cash value and potential upside through CVRs, which is a structured exit for shareholders. The unanimous board approval and significant shareholder support indicate a favorable internal view of the terms. However, the speculative nature of CVRs and the cessation of direct development activities temper the overall sentiment.

Positives

• The acquisition provides immediate cash value of $1.95 per share to stockholders, offering a certain return.
• The Contingent Value Right (CVR) offers potential additional upside from remaining cash, lease savings, and future monetization of the norovirus vaccine programs.
• The HilleVax Board of Directors unanimously approved the transaction, indicating strong internal support and belief in its fairness and best interests for stockholders.
• Support agreements from stockholders representing approximately 22.9% of outstanding shares increase the likelihood of the tender offer's success.
• The Buyer Entities' obligation to consummate the Offer and Merger is not subject to a financing condition, reducing transaction risk.
• The termination of the Takeda License Agreement for HIL-214 occurred without material early termination penalties, streamlining the company's asset portfolio.
• The sublease of a significant portion of the Boston office space to Stellaromics, Inc. helps mitigate future lease obligations and contributes to potential CVR payments.

Negatives

• The CVRs are non-transferable, limiting liquidity for stockholders who may wish to sell their contingent rights.
• Payments under the CVR are highly speculative and contingent on future events, with no guarantee that any payments will be made.
• The CVR payments for norovirus vaccine programs are tied to specific timeframes (within five years of regulatory approval, and disposition/financing within two years of closing), adding significant uncertainty.
• The cash component of $1.95 per share may be considered low by some investors, especially given the company's prior focus as a clinical-stage biopharmaceutical company.
• The termination of the Takeda License Agreement for HIL-214 signifies the winding down of a primary development asset, indicating a shift away from direct vaccine development.
• HilleVax is required to pay a termination fee of $2.475 million to Parent under certain circumstances, such as entering into a superior proposal.
• HilleVax may be required to pay an expense reimbursement fee of up to $990,000 to Parent if the Minimum Cash Condition is not satisfied.

Risks

• Uncertainties exist regarding the timing and ultimate completion of the tender offer and the merger.
• There is a risk that the required percentage of HilleVax stockholders may not tender their shares in the offer.
• The possibility of competing offers being made could complicate or delay the transaction.
• Various closing conditions for the tender offer or merger may not be satisfied or waived, including the failure to receive required regulatory approvals.
• The milestones related to the contingent value right may not be achieved, resulting in no CVR payments to stockholders.
• The transaction could cause disruption, making it more difficult for HilleVax to maintain relationships with employees, collaborators, vendors, and other business partners.
• Diverting management's attention from HilleVax's ongoing business operations due to the transaction poses a risk.
• Stockholder litigation in connection with the transactions could result in significant costs for defense, indemnification, and liability.
• The CVRs are contractual rights only, not securities, and will not be registered with the SEC, nor will they have voting or dividend rights or represent an equity interest in Parent.
• The CVRs are non-transferable, except in limited circumstances, restricting holders' ability to monetize them.
• Parent and its Affiliates retain discretion to control their businesses and assets, prioritizing their own stockholders' interests over those of CVR holders, which could impact CVR value.
• Parent is not obligated to initiate litigation against the Landlord for lease-related issues, potentially limiting recovery of lease savings for CVR holders.

Future Outlook

The acquisition is expected to close in September 2025, transitioning HilleVax into a wholly-owned subsidiary of XOMA Royalty. The future outlook for HilleVax stockholders includes a fixed cash payment and potential contingent cash payments via CVRs, tied to the company's final net cash, savings from its Boston office lease, and the future monetization of its norovirus vaccine programs (HIL-216). The HIL-214 program, previously licensed from Takeda, is being wound down.

Management Comments

• HilleVax's Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all HilleVax stockholders and has unanimously approved the Merger Agreement and related transactions.

Industry Context

This transaction signifies a strategic pivot for HilleVax, moving from an independent clinical-stage biopharmaceutical company focused on vaccine development to being acquired by a biotechnology royalty aggregator. XOMA Royalty's business model centers on acquiring future economics from therapeutic candidates, providing non-dilutive funding. The termination of the Takeda License Agreement for HIL-214 and the focus on monetizing the norovirus vaccine programs (HIL-216) through a CVR structure align with XOMA's strategy of extracting value from assets without direct, long-term development commitment. This reflects a broader industry trend where smaller biotechs, especially those facing late-stage development challenges or seeking strategic exits, may be acquired for their intellectual property or remaining assets by companies specializing in royalty streams or asset management.

Management Changes

Corporate Governance

Legal Proceedings

• Risk of stockholder litigation in connection with the transactions contemplated by the Merger Agreement, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Tender and support agreements were entered into with certain HilleVax officers, directors, and stockholders, who collectively hold approximately 22.9% of the outstanding shares of HilleVax common stock, committing them to tender their shares in the Offer.

Stakeholder Impact

• Shareholders: Will receive $1.95 cash per share and a non-transferable CVR, offering a fixed return plus potential contingent upside. However, the CVR's non-transferability limits liquidity, and its value is speculative.
• Employees/Officers/Directors: Equity awards will accelerate vesting and convert to cash and CVRs. Management changes will occur post-merger, with Merger Sub's leadership taking over. Potential for severance or change-in-control payments.
• Customers/Collaborators/Vendors: The transaction, particularly the termination of the Takeda License Agreement and the winding down of certain programs, may disrupt existing relationships.
• Takeda Vaccines, Inc.: The License Agreement for HIL-214 was terminated, ending their collaboration with HilleVax on that program.
• Stellaromics, Inc.: Will become a subtenant of HilleVax's Boston office space, securing a lease for a portion of the premises.

Next Steps

• Buyer Entities are required to commence the tender offer by August 18, 2025.
• HilleVax will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• The acquisition is expected to close in September 2025.
• Following the tender offer, Merger Sub will merge into HilleVax, with HilleVax surviving as a wholly-owned subsidiary of Parent.
• HilleVax's securities will be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time, and in any event no more than ten days after the Merger Closing Date.
• Potential future contingent cash payments will be made to CVR holders based on net cash, lease savings, and norovirus vaccine program monetization.
• The termination of the Takeda License Agreement for HIL-214 will become effective six months after August 1, 2025.
• The sublease with Stellaromics, Inc. is expected to commence on the later of Landlord consent, November 1, 2025, or two weeks after possession delivery.
• HilleVax will terminate any and all 401(k) plans effective immediately preceding the Effective Time.

Key Dates

Recommendation

For existing shareholders, holding through the tender offer is the logical next step to receive the full consideration, including the contingent value rights (CVRs). The non-transferable nature of the CVR means there is no immediate market for it, so selling shares before the tender offer would mean forfeiting the potential, albeit speculative, upside from the CVR. For new investors, the immediate upside is limited to the uncertain value of the CVR, and the company's core development activities are winding down, making it less attractive as a new investment. The fixed cash price provides a floor, but the CVR's value is highly uncertain, leading to a 'hold' recommendation for current shareholders rather than a 'buy' for new ones.

Keywords

HilleVax, XOMA Royalty, Merger Agreement, Tender Offer, Contingent Value Right, CVR, Biopharmaceutical, Vaccine, Norovirus, HIL-216, HIL-214, Acquisition, Corporate Governance, Lease Sublease, Asset Disposition, Royalty Aggregator, SEC Filing